Targeting tetraspanins in cancer

Expert Opinion on Therapeutic Targets

Volumn 16, Issue 10, 2012, Pages 985-997

  Sala Valdés, Mónica ^a,b   Ailane, Naouel ^a,b   Greco, Céline ^a,b   Rubinstein, Eric ^a,b   Boucheix, Claude ^a,b  

^a HÔPITAL PAUL BROUSSE   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Cancer; Monoclonal antibodies; SiRNA; Targeted therapy; Tetraspanin; Tetraspanin enriched microdomains

Indexed keywords

BETA1 INTEGRIN; CD151 ANTIGEN; CD37 ANTIGEN; CD53 ANTIGEN; CD63 ANTIGEN; CD81 ANTIGEN; CD82 ANTIGEN; CD9 ANTIGEN; MEMBRANE PROTEIN; OCULOSPANIN; PERIPHERIN; TETRASPAN PROTEIN SB134; TETRASPANIN; TETRASPANIN 11; TETRASPANIN 12; TETRASPANIN 13; TETRASPANIN 14; TETRASPANIN 15; TETRASPANIN 16; TETRASPANIN 17; TETRASPANIN 18; TETRASPANIN 19; TETRASPANIN 4; TETRASPANIN 5; TETRASPANIN 6; TETRASPANIN 7; TETRASPANIN 8; TETRASPANIN 9; UNCLASSIFIED DRUG; UROPLAKIN 1A; UROPLAKIN 1B;

BIOLOGICAL ACTIVITY; CANCER THERAPY; CARCINOGENESIS; HUMAN; NEOPLASM; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; SEQUENCE ANALYSIS;

ANIMALS; HUMANS; NEOPLASMS; TETRASPANINS;

EID: 84866496660     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2012.712688     Document Type: Review

References (104)

1. Andersen MH, Junker N, Ellebaek E, et al. Therapeutic cancer vaccines in combination with conventional therapy. J Biomed Biotechnol 2010;2010:237623
2. Blanco E, Hsiao A, Ruiz-Esparza GU, et al. Molecular-targeted nanotherapies in cancer: enabling treatment specificity. Mol Oncol 2011;5:492-503
3. Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer 2012;12:278-87
4. Leibovici J, Itzhaki O, Huszar M, Sinai J. The tumor microenvironment: part 1. Immunotherapy 2011;3:1367-84
5. Hanna E, Quick J, Libutti SK. The tumour microenvironment: a novel target for cancer therapy. Oral Dis 2009;15:8-17
6. Kohler G, Milstein C. Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion. Eur J Immunol 1976;6:511-19
7. Winter G, Harris WJ. Humanized antibodies. Immunol Today 1993;14:243-6 (Pubitemid 23186983)
8. Chan AC, Carter PJ. Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol 2010;10:301-16
9. Hemler ME. Targeting of tetraspanin proteins-potential benefits and strategies. Nat Rev Drug Discov 2008;7:747-58
10. Yanez-Mo M, Barreiro O, Gordon-Alonso M, et al. Tetraspanin-enriched microdomains: a functional unit in cell plasma membranes. Trends Cell Biol 2009;19:434-46
11. Charrin S, le Naour F, Silvie O, et al. Lateral organization of membrane proteins: tetraspanins spin their web. Biochem J 2009;420:133-54
12. Boucheix C, Rubinstein E. Tetraspanins. Cell Mol Life Sci 2001;58:1189-205 (Pubitemid 32844093)
13. Greco C, Bralet MP, Ailane N, et al. E-cadherin/p120-catenin and tetraspanin Co-029 cooperate for cell motility control in human colon carcinoma. Cancer Res 2010;70:7674-83
14. Zoller M. Tetraspanins: push and pull in suppressing and promoting metastasis. Nat Rev Cancer 2009;9:40-55
15. Chaput N, Thery C. Exosomes: immune properties and potential clinical implementations. Semin Immunopathol 2011;33:419-40
16. Valadi H, Ekstrom K, Bossios A, et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 2007;9:654-9 (Pubitemid 47214727)
17. Hemler ME. Tetraspanin functions and associated microdomains. Nat Rev Mol Cell Biol 2005;6:801-11 (Pubitemid 41726118)
18. Levy S, Shoham T. The tetraspanin web modulates immune-signalling complexes. Nat Rev Immunol 2005;5:136-48 (Pubitemid 40208903)
19. Audran R, Drenou B, Wittke F, et al. Internalization of human macrophage surface antigens induced by monoclonal antibodies. J Immunol Methods 1995;188:147-54 (Pubitemid 26014806)
20. Chometon G, Zhang ZG, Rubinstein E, et al. Dissociation of the complex between CD151 and laminin-binding integrins permits migration of epithelial cells. Exp Cell Res 2006;312:983-95
21. Nishiuchi R, Sanzen N, Nada S, et al. Potentiation of the ligand-binding activity of integrin alpha3beta1 via association with tetraspanin CD151. Proc Natl Acad Sci USA 2005;102:1939-44 (Pubitemid 40261991)
22. Hassuna N, Monk PN, Moseley GW, Partridge LJ. Strategies for targeting tetraspanin proteins: potential therapeutic applications in microbial infections. Bio Drugs 2009;23:341-59
23. Barreiro O, Zamai M, Yanez-Mo M, et al. Endothelial adhesion receptors are recruited to adherent leukocytes by inclusion in preformed tetraspanin nanoplatforms. J Cell Biol 2008;183:527-42
24. Hemler ME. Tetraspanin proteins mediate cellular penetration, invasion, and fusion events and define a novel type of membrane microdomain. Annu Rev Cell Dev Biol 2003;19:397-422 (Pubitemid 37487354)
25. Monk PN, Partridge LJ. Tetraspanins - gateways for infection. Infect Disord Drug Targets 2012;12:4-17
26. Barreiro O, Yanez-Mo M, Sala-Valdes M, et al. Endothelial tetraspanin microdomains regulate leukocyte firm adhesion during extravasation. Blood 2005;105:2852-61 (Pubitemid 40446279)
27. Yang C, Robbins PD. The roles of tumor-derived exosomes in cancer pathogenesis. Clin Dev Immunol 2011;2011:842849
28. Ristorcelli E, Beraud E, Verrando P, et al. Human tumor nanoparticles induce apoptosis of pancreatic cancer cells. FASEB J 2008;22:3358-69
29. Filipazzi P, Burdek M, Villa A, et al. Recent advances on the role of tumor exosomes in immunosuppression and disease progression. Semin Cancer Biol 2012;22:342-9
30. Somasundaram R, Herlyn M. Melanoma exosomes: messengers of metastasis. Nat Med 2012;18:853-4
31. Berthier-Vergnes O, Kharbili ME, de la Fouchardiere A, et al. Gene expression profiles of human melanoma cells with different invasive potential reveal TSPAN8 as a novel mediator of invasion. Br J Cancer 2011;104:155-65
32. Tarasova NI, Rice WG, Michejda CJ. Inhibition of G-protein-coupled receptor function by disruption of transmembrane domain interactions. J Biol Chem 1999;274:34911-15 (Pubitemid 129509538)
33. Charrin S, Manie S, Oualid M, et al. Differential stability of tetraspanin/tetraspanin interactions: role of palmitoylation. FEBS Lett 2002;516:139-44 (Pubitemid 34311950)
34. Takeda T, Hattori N, Tokuhara T, et al. Adenoviral transduction of MRP-1/CD9 and KAI1/CD82 inhibits lymph node metastasis in orthotopic lung cancer model. Cancer Res 2007;67:1744-9 (Pubitemid 46383401)
35. Krause G, Patz M, Isaeva P, et al. Action of novel CD37 antibodies on chronic lymphocytic leukemia cells. Leukemia 2012;26:546-9
36. Kaminski MS, Fig LM, Zasadny KR, et al. Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma. J Clin Oncol 1992;10:1696-711 (Pubitemid 23059946)
37. Jaglowski SM, Alinari L, Lapalombella R, et al. The clinical application of monoclonal antibodies in chronic lymphocytic leukemia. Blood 2010;116:3705-14
38. Zhao X, Lapalombella R, Joshi T, et al. Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical. Blood 2007;110:2569-77 (Pubitemid 47527052)
39. Jin L, Cambier JC. SMIP-016 in Action: CD37 as a Death Receptor. Cancer Cell 2012;21:597-8
40. Lapalombella R, Yeh YY, Wang L, et al. Tetraspanin CD37 Directly Mediates Transduction of Survival and Apoptotic Signals. Cancer Cell 2012;21:694-708
41. Robak T, Robak P, Smolewski P. TRU-016, a humanized anti-CD37 IgG fusion protein for the potential treatment of B-cell malignancies. Curr Opin Investig Drugs 2009;10:1383-90
42. Schnaiter A, Stilgenbauer S. Refractory chronic lymphocytic leukemia-new therapeutic strategies. Oncotarget 2010;1:472-82
43. Phase I/Ib Study of TRU-016 in Patients With Previously Treated CLL or Select Subtypes of Non-Hodgkin's Lymphoma. 2012.Avaulable from http://clinicaltrialsfeeds.org/clinical-trials/show/NCT00614042
44. Heider KH, Kiefer K, Zenz T, et al. A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies. Blood 2011;118:4159-68
45. Sincock PM, Mayrhofer G, Ashman LK. Localization of the transmembrane 4 superfamily (TM4SF) member PETA-3 (CD151) in normal human tissues: comparison with CD9, CD63, and alpha5beta1 integrin. J Histochem Cytochem 1997;45:515-25 (Pubitemid 27175796)
46. Kwon MJ, Park S, Choi JY, et al. Clinical significance of CD151 overexpression in subtypes of invasive breast cancer. Br J Cancer 2012;106:923-30
47. Ke AW, Shi GM, Zhou J, et al. Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma. Hepatology 2009;49:491-503
48. Lin PC, Lin SC, Lee CT, et al. Dynamic change of tetraspanin CD151 membrane protein expression in colorectal cancer patients. Cancer Invest 2011;29:542-7
49. Semenza GL. Does loss of CD151 expression promote the metastasis of hypoxic colon cancer cells? Clin Cancer Res 2008;14:7969-70
50. Chien CW, Lin SC, Lai YY, et al. Regulation of CD151 by hypoxia controls cell adhesion and metastasis in colorectal cancer. Clin Cancer Res 2008;14:8043-51
51. Kohno M, Hasegawa H, Miyake M, et al. CD151 enhances cell motility and metastasis of cancer cells in the presence of focal adhesion kinase. Int J Cancer 2002;97:336-43 (Pubitemid 34049024)
52. Yoo SH, Lee K, Chae JY, Moon KC. CD151 expression can predict cancer progression in clear cell renal cell carcinoma. Histopathology 2011;58:191-7
53. Voss MA, Gordon N, Maloney S, et al. Tetraspanin CD151 is a novel prognostic marker in poor outcome endometrial cancer. Br J Cancer 2011;104:1611-18
54. Tokuhara T, Hasegawa H, Hattori N, et al. Clinical significance of CD151 gene expression in non-small cell lung cancer. Clin Cancer Res 2001;7:4109-14 (Pubitemid 34044635)
55. Ang J, Fang BL, Ashman LK, Frauman AG. The migration and invasion of human prostate cancer cell lines involves CD151 expression. Oncol Rep 2010;24:1593-7
56. Devbhandari RP, Shi GM, Ke AW, et al. Profiling of the tetraspanin CD151 web and conspiracy of CD151/integrin beta1 complex in the progression of hepatocellular carcinoma. PLoS One 2011;6:e24901
57. Sadej R, Romanska H, Kavanagh D, et al. Tetraspanin CD151 regulates transforming growth factor beta signaling: implication in tumor metastasis. Cancer Res 2010;70:6059-70
58. Zijlstra A, Lewis J, Degryse B, et al. The inhibition of tumor cell intravasation and subsequent metastasis via regulation of in vivo tumor cell motility by the tetraspanin CD151. Cancer Cell 2008;13:221-34 (Pubitemid 351318371)
59. Haeuw JF, Goetsch L, Bailly C, Corvaia N. Tetraspanin CD151 as a target for antibody-based cancer immunotherapy. Biochem Soc Trans 2011;39:553-8
60. Takeda Y, Kazarov AR, Butterfield CE, et al. Deletion of tetraspanin Cd151 results in decreased pathologic angiogenesis in vivo and in vitro. Blood 2007;109:1524-32 (Pubitemid 46239585)
61. Zheng ZZ, Liu ZX. CD151 gene delivery increases eNOS activity and induces ECV304 migration, proliferation and tube formation. Acta Pharmacol Sin 2007;28:66-72
62. Mosig RA, Lin L, Senturk E, et al. Application of RNA-Seq transcriptome analysis: CD151 is an Invasion/Migration target in all stages of epithelial ovarian cancer. J Ovarian Res 2012;5:4
63. Yang XH, Flores LM, Li Q, et al. Disruption of laminin-integrin-CD151- focal adhesion kinase axis sensitizes breast cancer cells to ErbB2 antagonists. Cancer Res 2010;70:2256-63
64. Boucheix C, Duc GH, Jasmin C, Rubinstein E. Tetraspanins and malignancy. Expert Rev Mol Med 2001;2001:1-17
65. Boucheix C, Perrot JY, Mirshahi M, et al. A new set of monoclonal antibodies against acute lymphoblastic leukemia. Leuk Res 1985;9:597-604 (Pubitemid 15059259)
66. Ovalle S, Gutierrez-Lopez MD, Olmo N, et al. The tetraspanin CD9 inhibits the proliferation and tumorigenicity of human colon carcinoma cells. Int J Cancer 2007;121:2140-52 (Pubitemid 47585592)
67. Chen S, Sun Y, Jin Z, Jing X. Functional and biochemical studies of CD9 in fibrosarcoma cell line. Mol Cell Biochem 2011;350:89-99
68. Ikeyama S, Koyama M, Yamaoko M, et al. Suppression of cell motility and metastasis by transfection with human motility-related protein (MRP-1/CD9) DNA. J Exp Med 1993;177:1231-7 (Pubitemid 23117114)
69. Saito Y, Tachibana I, Takeda Y, et al. Absence of CD9 enhances adhesion-dependent morphologic differentiation, survival, and matrix metalloproteinase-2 production in small cell lung cancer cells. Cancer Res 2006;66:9557-65 (Pubitemid 44623654)
70. Sho M, Adachi M, Taki T, et al. Transmembrane 4 superfamily as a prognostic factor in pancreatic cancer. Int J Cancer 1998;79:509-16 (Pubitemid 28445274)
71. Erovic BM, Pammer J, Hollemann D, et al. Motility-related protein-1/CD9 expression in head and neck squamous cell carcinoma. Head Neck 2003;25:848-57 (Pubitemid 37139897)
72. Kohmo S, Kijima T, Otani Y, et al. Cell surface tetraspanin CD9 mediates chemoresistance in small cell lung cancer. Cancer Res 2010;70:8025-35
73. Nakamoto T, Murayama Y, Oritani K, et al. A novel therapeutic strategy with anti-CD9 antibody in gastric cancers. J Gastroenterol 2009;44:889-96
74. Furuya M, Kato H, Nishimura N, et al. Down-regulation of CD9 in human ovarian carcinoma cell might contribute to peritoneal dissemination: morphologic alteration and reduced expression of beta1 integrin subsets. Cancer Res 2005;65:2617-25 (Pubitemid 40490060)
75. Park KR, Inoue T, Ueda M, et al. Anti-CD9 monoclonal antibody-stimulated invasion of endometrial cancer cell lines in vitro: possible inhibitory effect of CD9 in endometrial cancer invasion. Mol Hum Reprod 2000;6:719-25 (Pubitemid 30627517)
76. Hwang JR, Jo K, Lee Y, et al. Upregulation of CD9 in ovarian cancer is related to the induction of TNF-alpha gene expression and constitutive NF-kappaB activation. Carcinogenesis 2012;33:77-83
77. Longo N, Yanez-Mo M, Mittelbrunn M, et al. Regulatory role of tetraspanin CD9 in tumor-endothelial cell interaction during transendothelial invasion of melanoma cells. Blood 2001;98:3717-26
78. Wang HX, Kolesnikova TV, Denison C, et al. The C-terminal tail of tetraspanin protein CD9 contributes to its function and molecular organization. J Cell Sci 2011;124:2702-10
79. Szala S, Kasai Y, Steplewski Z, et al. Molecular cloning of cDNA for the human tumor-associated antigen CO-029 and identification of related transmembrane antigens. Proc Natl Acad Sci USA 1990;87:6833-7
80. Kanetaka K, Sakamoto M, Yamamoto Y, et al. Possible involvement of tetraspanin CO-029 in hematogenous intrahepatic metastasis of liver cancer cells. J Gastroenterol Hepatol 2003;18:1309-14 (Pubitemid 37464007)
81. Zhou Z, Ran YL, Hu H, et al. TM4SF3 promotes esophageal carcinoma metastasis via upregulating ADAM12m expression. Clin Exp Metastasis 2008;25:537-48
82. Claas C, Seiter S, Claas A, et al. Association between the rat homologue of CO-029, a metastasis-associated tetraspanin molecule and consumption coagulopathy. J Cell Biol 1998;141:267-80 (Pubitemid 28182657)
83. Nazarenko I, Rana S, Baumann A, et al. Cell surface tetraspanin Tspan8 contributes to molecular pathways of exosome-induced endothelial cell activation. Cancer Res 2010;70:1668-78
84. Tonoli H, Barrett JC. CD82 metastasis suppressor gene: a potential target for new therapeutics? Trends Mol Med 2005;11:563-70 (Pubitemid 41713998)
85. Romanska HM, Berditchevski F. Tetraspanins in human epithelial malignancies. J Pathol 2011;223:4-14
86. Jang HI, Lee H. A decrease in the expression of CD63 tetraspanin protein elevates invasive potential of human melanoma cells. Exp Mol Med 2003;35:317-23 (Pubitemid 37152647)
87. Chen L, Yuan D, Zhao R, et al. Suppression of TSPAN1 by RNA interference inhibits proliferation and invasion of colon cancer cells in vitro. Tumori 2010;96:744-50
88. Chen L, Zhu Y, Li H, et al. Knockdown of TSPAN1 by RNA silencing and antisense technique inhibits proliferation and infiltration of human skin squamous carcinoma cells. Tumori 2010;96:289-95
89. Bennett G, Sadlier D, Doran PP, et al. A functional and transcriptomic analysis of NET1 bioactivity in gastric cancer. BMC Cancer 2011;11:50
90. Huang H, Sossey-Alaoui K, Beachy SH, Geradts J. The tetraspanin superfamily member NET-6 is a new tumor suppressor gene. J Cancer Res Clin Oncol 2007;133:761-9 (Pubitemid 47319242)
91. Arencibia JM, Martin S, Perez-Rodriguez FJ, Bonnin A. Gene expression profiling reveals overexpression of TSPAN13 in prostate cancer. Int J Oncol 2009;34:457-63
92. Prox J, Willenbrock M, Weber S, et al. Tetraspanin15 regulates cellular trafficking and activity of the ectodomain sheddase ADAM10. Cell Mol Life Sci 2012; online 25 March 2012
93. Xu D, Sharma C, Hemler ME. Tetraspanin12 regulates ADAM10-dependent cleavage of amyloid precursor protein. FASEB J 2009;23:3674-81
94. Mochizuki S, Okada Y. ADAMs in cancer cell proliferation and progression. Cancer Sci 2007;98:621-8 (Pubitemid 46563436)
95. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 2010;10:9-22
96. CLINICAL TRIALS. Available from: http://www.clinicaltrials.gov/
97. Klosek SK, Nakashiro K, Hara S, et al. CD151 regulates HGF-stimulated morphogenesis of human breast cancer cells. Biochem Biophys Res Commun 2009;379:1097-100
98. Vosjan MJ, Vercammen J, Kolkman JA, et al. Nanobodies Targeting the Hepatocyte Growth Factor: Potential New Drugs for Molecular Cancer Therapy. Mol Cancer Ther 2012;11:1017-25
99. Murayama Y, Shinomura Y, Oritani K, et al. The tetraspanin CD9 modulates epidermal growth factor receptor signaling in cancer cells. J Cell Physiol 2008;216:135-43 (Pubitemid 351813104)
100. Odintsova E, Sugiura T, Berditchevski F. Attenuation of EGF receptor signaling by a metastasis suppressor, the tetraspanin CD82/KAI-1. Curr Biol 2000;10:1009-12
101. Yanez-Mo M, Gutierrez-Lopez MD, Cabanas C. Functional interplay between tetraspanins and proteases. Cell Mol Life Sci 2011;68:3323-35
102. Remacle AG, Golubkov VS, Shiryaev SA, et al. Novel MT1-MMP small-molecule inhibitors based on insights into hemopexin domain function in tumor growth. Cancer Res 2012;72:2339-49
103. Kolesnikova TV, Kazarov AR, Lemieux ME, et al. Glioblastoma inhibition by cell surface immunoglobulin protein EWI-2, in vitro and in vivo. Neoplasia 2009;11:77-86.
104. Colin S, Guilmain W, Creoff E, et al. A truncated form of CD9-partner 1 (CD9P-1), GS-168AT2, potently inhibits in vivo tumour-induced angiogenesis and tumour growth. Br J Cancer 2011;105:1002-11